1 / 8

RENAAL Baseline Characteristics (I)

RENAAL Baseline Characteristics (I). Losartan (+CT) (n=751) 60 62 39 16 17 48 19 2 152 82 30. Placebo (+CT) (n=762) 60 65 35 18 14 50 18 1 153 82 29. Age, years Male, % Female, %

zamir
Download Presentation

RENAAL Baseline Characteristics (I)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. RENAAL Baseline Characteristics (I) Losartan (+CT) (n=751) 60 62 39 16 17 48 19 2 152 82 30 Placebo (+CT) (n=762) 60 65 35 18 14 50 18 1 153 82 29 Age, years Male, % Female, % Race, % Asian Black Caucasian Hispanic Other Systolic (mmHg) Diastolic (mmHg) BMI (kg/m2) % Brenner BM et al New Engl J Med 2001;345(12):861-869.

  2. RENAAL Baseline Characteristics (II) Losartan (+CT) (n=751) % 92 9 10 0.1 0 31 9 50 66 20 Placebo (+CT) (n=762) % 95 10 12 0.1 0.1 36 9 50 62 17 Medical History Treatment for Hypertension Angina Pectoris Myocardial Infarction Coronary Revascularization Stroke Lipid Disorders Amputation Neuropathy Retinopathy Smoking (current) Brenner BM et al New Engl J Med 2001;345(12):861-869.

  3. RENAAL Baseline Characteristics (III) Losartan (+CT) (n=751) 1237 1.9 227 142 45 213 12.5 8.5 Placebo (+CT) (n=762) 1261 1.9 229 142 45 225 12.5 8.4 Laboratory Urinary alb:creat (median) (mg/g) Serum Creatinine (mg/dL) Serum Cholesterol (mg/dL) Total LDL HDL Serum Triglycerides (mg/dL) Hemoglobin (g/dL) Glycosylated Hemoglobin (%) p=NS for all values Brenner BM et al New Engl J Med 2001;345(12):861-869.

  4. RENAAL Primary Components ESRD 30 Risk Reduction: 28% p=0.002 P (+CT) 20 % with event L (+CT) Doubling of Serum Creatinine 10 Risk Reduction: 25% 0 30 p=0.006 0 12 24 36 48 Months P (+CT) P (+ CT) 762 715 610 347 42 20 751 714 625 375 69 L (+ CT) L (+CT) % with event 50 ESRD or Death 10 40 Risk Reduction: 20% p=0.01 P (+CT) 0 30 0 12 24 36 48 % with event L (+CT) 20 Months P (+ CT) 295 762 689 554 36 10 L (+ CT) 52 751 692 583 329 0 0 12 24 36 48 Brenner BM et al New Engl J Med2001;345(12):861-869. Months P (+ CT) 762 715 610 347 42 L (+ CT) 751 714 625 375 69

  5. 20 15 10 5 0 RENAALFirst Hospitalization for Heart Failure Risk Reduction: 32% p=0.005 P (+CT) % with event L (+CT) 0 12 24 36 48 Months P (+CT) 762 685 616 375 53 L (+CT) 751 701 637 388 74 Brenner BM et al New Engl J Med 2001;345(12):861-869.

  6. RENAALChange from Baseline in Proteinuria 40 20 P (+CT) 0 Median Percent Change p<0.001 -20 35% Overall Reduction -40 L (+CT) -60 0 12 24 36 48 Months P (+CT) 762 632 529 390 130 130 130 130 130 130 L (+CT) 751 661 558 438 167 167 167 167 167 167 Proteinuria measured as the urine albumin:creatinine ratio from a first morning void. Brenner BM et al New Engl J Med 2001;345(12):861-869.

  7. RENAALMost Common Clinical and Laboratory Adverse Experiences Leading to Discontinuation of Study Therapy 6% 6 (+CT) Losartan (+CT) Placebo 4 3% 3% Percentage 2% 2% 2 1.5% 1% 1% 1% 1% 1.2% 1.1% 1% 0.5% 0 Heart ESRD Myocard. Stroke Worsening sCr Hyper- Failure infarction renal increased kalemia insufficiency Laboratory AE Clinical AE Presented by Brenner B. Reduction of endpoints in non-insulin-dependent diabetes mellitus with angiotensin II antagonist losartan. Program and abstracts of the 16th Annual Meeting of the American Society of Hypertension; May 16-19, 2001; San Francisco, California

  8. RENAAL Summary • In patients with Type 2 diabetes and nephropathy: • losartan delayed the onset of the primary composite endpoint (DsCr/ESRD/Death) and delayed the progression to ESRD. • losartan reduced proteinuria and the rate of decline in renal function (1/sCr slope). • losartan reduced the incidence of hospitalization for heart failure. • these benefits were largely independent of achieved blood pressure. • losartan and placebo, on a background of conventional therapy, showed no significant difference on all-cause mortality, MI, stroke, revascularization, hospitalizations for unstable angina, and death due to CV disease. • losartan was generally well tolerated in this patient population. Brenner BM et al New Engl J Med 2001;345(12):861-869.

More Related